

ESMO 2019 INDUSTRY SATELLITE SYMPOSIUM

WHAT POTENTIAL DO TKIs HAVE TO OPTIMIZE OUTCOMES IN REFRACTORY mCRC AND uHCC?

Friday September 27, 2019; 18:00–20:00

Oviedo Auditorium, CC5, Fira Gran Via, Barcelona, Spain

SAVE THE DATE

Contribute to the faculty debate with your own clinical experience in this interactive symposium, utilizing patient cases & audience-driven hot topics

CHAIR

Eric Van Cutsem, Belgium

FACULTY

Heinz-Josef Lenz, USA

Axel Grothey, USA

Tanios Bekaii-Saab, USA

Guillem Argilés, Spain

Michel Ducreux, France

Chris Verslype, Belgium



WHAT POTENTIAL DO TKIs HAVE TO OPTIMIZE OUTCOMES IN REFRACTORY mCRC AND uHCC?

AGENDA

- 18:00-18:05** Introduction: TKI evolution in GI cancers
Eric Van Cutsem, Belgium
- 18:05-18:25** What is the role for TKIs in the era of immunotherapy in GI cancers?
Heinz-Josef Lenz, USA
- 18:25-19:25** How can we optimize outcomes for refractory mCRC patients with TKIs?
An interactive case study panel discussion
Axel Grothey, USA
Tanios Bekaii-Saab, USA
Guillem Argilés, Spain
Michel Ducreux, France
- 19:25-19:45** How do we navigate the unresectable HCC treatment landscape?
Chris Verslype, Belgium
- 19:45-19:55** Panel Q&A: Select your most pressing question for an expert panel discussion
1. How should we sequence available agents in third-line mCRC to optimize outcomes?
2. How relevant is duration of therapy in optimizing outcomes in third-line mCRC?
3. Where do we go next with TKIs in mCRC?
4. How may recent evidence and patient characteristics help sequencing decisions in uHCC?
Chair and Faculty
- 19:55-20:00** Summary & Closing
Eric Van Cutsem, Belgium